Synergism of cyclin-Dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines

Molecules

Volumn 19, Issue 2, 2014, Pages 2077-2088

  Hamilton, Gerhard ^a,b   Klameth, Lukas ^a,c   Rath, Barbara ^a   Thalhammer, Theresia ^c  

^a Ludwig Boltzmann Cluster of Translational Oncology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Camptothecin; Cyclin dependent; Rubitecan; Small cell lung cancer; Topotecan

Indexed keywords

9 AMINOCAMPTOTHECIN; 9-AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE; DRUG DERIVATIVE; ENZYME INHIBITOR; IRINOTECAN; RUBITECAN; TOPOTECAN;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; LUNG SMALL CELL CANCER; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 84894636613     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19022077     Document Type: Article

References (22)

1. Youlden, D.R.; Cramb, S.M.; Baade, P.D. The International Epidemiology of Lung Cancer: Geographical distribution and secular trends. J. Thoracic Oncol. 2008, 3, 819-831.
2. Califano, A.; Abidin, Z.; Peck, R.; Faivre-Finn, C.; Lorigan, P.R. Management of small cell lung cancer: Recent developments for optimal care. Drugs 2012, 72, 471-490.
3. William W.N.; Glisson, B.S. Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 2011, 8, 611-619.
4. Schmittel, A. Second-line therapy for small-cell lung cancer. Expert Rev. Anticancer Ther. 2011, 11, 631-637.
5. Tomicic, M.T.; Kaina, B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim. Biophys. Acta 2013, 1835, 11-27.
6. Wal, M.E.; Wani, M.C.; Cooke, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
7. Pommier, Y. Camptothecins and topoisomerase I: A foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: Importance of DNA replication, repair and cell cycle checkpoints. Curr. Med. Chem. Anticancer Agents 2004, 4, 429-434.
8. Venditto, V.J.; Simanek, E.E. Cancer therapies utilizing the camptothecins: A review of the in vivo literature. Mol. Pharm. 2010, 7, 307-349.
9. Wani, M.C.; Wall, M.E. Plant antitumor agents. II. Structure of two new alkaloids from Camptotheca acuminata. J. Org. Chem. 1969, 34, 1364-1367.
10. Hertzberg, R.; Caranfa, M.J.; Holden, K.G.; Jakas, D.R.; Gallagher, G.; Mattern, M.R.; Mong, S.M.; Bartus, J.O.; Johnson, R.K.; Kingsbury, W.D. Modification of the hydroxylactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32, 715-720.
11. Supko, J.G.; Malspeis, L. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res. 1993, 53, 3062-3069.
12. Hinz, H.R.; Harris, N.J.; Natelson, E.A.; Giovanella, B.C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)- camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice. Cancer Res. 1994, 54, 3096-3100.
13. Hamilton, G.; Olszewski, U.; Klameth, L.; Ulsperger, E.; Geissler, K. Synergistic anticancer activity of topotecan- Cyclin-dependent kinase inhibitor combinations against drug-resistant Small Cell Lung Cancer (SCLC) cell lines. J. Cancer Ther. 2013, 4, 47-53.
14. Gallorini, M.; Cataldi, A.; di Giacomo, V. Cyclin-dependent kinase modulators and cancer therapy. BioDrugs 2012, 26, 377-391.
15. Schutte, B.; Nieland, L.; van Engeland, M.; Henfling, M.E.; Meijer, L.; Ramaekers, F.C. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res. 1997, 236, 4-15.
16. Fukuoka, K.; Adachi, J.; Nishio, K.; Arioka, H.; Kurokawa, H.; Fukumoto, H.; Ishida, T.; Nomoto, T.; Yokote, H.; Tomonari, A.; et al. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA Topoisomerase I Inhibitors. Jpn. J. Cancer Res. 1997, 88, 1009-1016.
17. Shu, K.X.; Li, B.; Wu, L.X. The p53 network: p53 and its downstream genes. Colloids Surf. B Biointerfaces 2007, 55, 10-18.
18. Otterson, G.A.; Kratzke, R.A.; Coxon, A.; Kim, Y.W.; Kaye, F.J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994, 9, 3375-3378.
19. Wikman, H.; Kettunen, E. Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Exp. Rev. Anticancer Ther. 2006, 6, 515-530.
20. Okamoto, A.; Hussain, S.P.; Hagiwara, K.; Spillare, E.A.; Rusin, M.R.; Demetrick, D.J.; Serrano, M.; Hannon, G.J.; Shiseki, M.; Zariwala, M.; et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995, 55, 1448-1451.
21. Zandi, R.; Selivanova, G.; Christensen, C.L. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 2011, 17, 2830-2841.
22. Abal, M.; Bras-Goncalves, R.; Judde, J.G.; Fsihi, H.; de Cremoux, P.; Louvard, D.; Magdelenat, H.; Robine, S.; Poupon, M.F. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-Deficient HT29 human colon cancer cell line. Oncogene 2004, 23, 1737-1744.